Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R. Baden, Hong‐Van Tieu, Georgia D. Tomaras et al.|The Lancet HIV|2020Cited by 91
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Varun K. Phadke, Dan H. Barouch et al.|The Journal of Infectious Diseases|2022Cited by 36